Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core US Aggregate Bond ETF
AGG
|
+$956M |
| 2 |
iShares Core S&P Total US Stock Market ETF
ITOT
|
+$924M |
| 3 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$769M |
| 4 |
Vanguard Morningstar Value ETF
VTV
|
+$410M |
| 5 |
Kenvue
KVUE
|
+$393M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 0-5 Year TIPS Bond ETF
STIP
|
+$411M |
| 2 |
Johnson & Johnson
JNJ
|
+$234M |
| 3 |
Cisco
CSCO
|
+$181M |
| 4 |
iShares Gold Trust
IAU
|
+$143M |
| 5 |
LSI
Life Storage, Inc.
LSI
|
+$135M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.03% |
| 2 | Healthcare | 12.31% |
| 3 | Financials | 11.79% |
| 4 | Consumer Discretionary | 9.84% |
| 5 | Industrials | 9.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1976
Opko Health
OPK
$978M
| $8.88M | ﹤0.01% |
5,549,946
+405,106
| +8% | +$738K |
|
1977
National Bank Holdings
NBHC
$1.94B
| $8.87M | ﹤0.01% |
298,048
+11,562
| +4% | +$370K |
|
1978
Zentalis Pharmaceuticals
ZNTL
$347M
| $8.87M | ﹤0.01% |
442,064
+36,219
| +9% | +$919K |
|
1979
Recursion Pharmaceuticals
RXRX
$1.76B
| $8.86M | ﹤0.01% |
1,157,966
+157,189
| +16% | +$1.57M |
|
1980
Certara
CERT
$1.21B
| $8.83M | ﹤0.01% |
607,030
+32,790
| +6% | +$551K |
|
1981
Rhythm Pharmaceuticals
RYTM
$7.26B
| $8.82M | ﹤0.01% |
384,748
+34,189
| +10% | +$766K |
|
1982
NovoCure
NVCR
$1.89B
| $8.74M | ﹤0.01% |
541,265
-1,988
| -0.4% | -$57.3K |
|
1983
LeMaitre Vascular
LMAT
$2.42B
| $8.72M | ﹤0.01% |
160,056
+9,193
| +6% | +$545K |
|
|
FBRT
1984
Franklin BSP Realty Trust
FBRT
$639M
| $8.72M | ﹤0.01% |
658,301
+25,636
| +4% | +$357K |
|
1985
Unitil
UTL
$964M
| $8.69M | ﹤0.01% |
203,573
+9,646
| +5% | +$472K |
|
|
EHAB
1986
DELISTED
Enhabit
EHAB
| $8.69M | ﹤0.01% |
772,840
+160,776
| +26% | +$2.02M |
|
1987
Phinia Inc
PHIN
$2.93B
| $8.65M | ﹤0.01% |
+322,929
| New | +$8.94M |
|
1988
Haverty Furniture Companies
HVT
$455M
| $8.62M | ﹤0.01% |
299,501
+7,620
| +3% | +$243K |
|
1989
Dine Brands
DIN
$442M
| $8.61M | ﹤0.01% |
174,178
+5,250
| +3% | +$293K |
|
1990
Argan
AGX
$8.66B
| $8.55M | ﹤0.01% |
187,937
-5,023
| -3% | -$207K |
|
1991
Capitol Federal Financial
CFFN
$1.13B
| $8.55M | ﹤0.01% |
1,793,378
+115,083
| +7% | +$680K |
|
1992
ANI Pharmaceuticals
ANIP
$1.8B
| $8.53M | ﹤0.01% |
146,989
+109,015
| +287% | +$6.29M |
|
1993
DXP Enterprises
DXPE
$2.65B
| $8.53M | ﹤0.01% |
244,082
-8,290
| -3% | -$299K |
|
1994
Green Brick Partners
GRBK
$3.1B
| $8.51M | ﹤0.01% |
204,934
-326
| -0.2% | -$16.3K |
|
1995
Harmonic Inc
HLIT
$1.34B
| $8.49M | ﹤0.01% |
882,104
+30,811
| +4% | +$367K |
|
1996
Viking Therapeutics
VKTX
$3.84B
| $8.47M | ﹤0.01% |
765,320
+505,578
| +195% | +$7.23M |
|
1997
Arvinas
ARVN
$581M
| $8.45M | ﹤0.01% |
429,990
+66,430
| +18% | +$1.63M |
|
1998
XP
XP
$8.77B
| $8.43M | ﹤0.01% |
365,562
+75,262
| +26% | +$1.89M |
|
|
SAGE
1999
DELISTED
Sage Therapeutics
SAGE
| $8.42M | ﹤0.01% |
408,987
+17,819
| +5% | +$515K |
|
2000
Sweetgreen
SG
$679M
| $8.41M | ﹤0.01% |
715,906
+107,281
| +18% | +$1.49M |
|
Similar funds
Charles Schwab's Q3 2023 Portfolio in Review
As of Q3 2023, Charles Schwab held 3,713 positions worth $349B, down 0.3% from $350B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Charles Schwab deployed $12.6B of net new capital in Q3 2023, opening 104 new positions and adding to 2,394 existing holdings. Its largest new stake was Vanguard Morningstar Value ETF: 2,862,740 shares worth $395M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Johnson & Johnson, an estimated $234M trimmed.
- Charles Schwab's largest Q3 2023 buy was Vanguard Morningstar Value ETF: 2,862,740 shares worth $395M.
- Charles Schwab added most to iShares Core US Aggregate Bond ETF in Q3 2023, an estimated $956M increase.
- Charles Schwab's biggest Q3 2023 reduction was Johnson & Johnson, cutting an estimated $234M.
- Charles Schwab fully exited iShares 0-5 Year TIPS Bond ETF in Q3 2023, selling an estimated $411M.
- Charles Schwab's ten largest holdings make up 18% of its $349B portfolio in Q3 2023.
- Charles Schwab opened 104 new positions and closed 137 in Q3 2023.
- Charles Schwab's portfolio value fell 0.3% quarter-over-quarter to $349B.
Based on Charles Schwab's 13F filing for Q3 2023, filed 8 Nov 2023.